JP2024504728A5 - - Google Patents

Info

Publication number
JP2024504728A5
JP2024504728A5 JP2023545206A JP2023545206A JP2024504728A5 JP 2024504728 A5 JP2024504728 A5 JP 2024504728A5 JP 2023545206 A JP2023545206 A JP 2023545206A JP 2023545206 A JP2023545206 A JP 2023545206A JP 2024504728 A5 JP2024504728 A5 JP 2024504728A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
domain
polypeptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023545206A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504728A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/073808 external-priority patent/WO2022161355A1/en
Publication of JP2024504728A publication Critical patent/JP2024504728A/ja
Publication of JP2024504728A5 publication Critical patent/JP2024504728A5/ja
Pending legal-status Critical Current

Links

JP2023545206A 2021-01-26 2022-01-25 キメラ抗原受容体（ｃａｒ）構築物およびｃａｒ構築物を発現するｎｋ細胞 Pending JP2024504728A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163141621P 2021-01-26 2021-01-26
US63/141,621 2021-01-26
PCT/CN2022/073808 WO2022161355A1 (en) 2021-01-26 2022-01-25 Chimeric antigen receptor (car) constructs and nk cells expressing car constructs

Publications (2)

Publication Number Publication Date
JP2024504728A JP2024504728A (ja) 2024-02-01
JP2024504728A5 true JP2024504728A5 (enExample) 2025-01-29

Family

ID=81327157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023545206A Pending JP2024504728A (ja) 2021-01-26 2022-01-25 キメラ抗原受容体（ｃａｒ）構築物およびｃａｒ構築物を発現するｎｋ細胞

Country Status (5)

Country Link
US (1) US20240115607A1 (enExample)
EP (1) EP4284394A1 (enExample)
JP (1) JP2024504728A (enExample)
CN (1) CN117062611A (enExample)
WO (1) WO2022161355A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
CN116286660B (zh) * 2022-12-08 2023-10-03 全球细胞控股(广州)有限公司 一种ipsc-（car）自然杀伤细胞、制备方法及其在肿瘤治疗中的应用
WO2025067205A1 (en) * 2023-09-25 2025-04-03 Nanjing Legend Biotech Co., Ltd. Engineered receptors and methods of use thereof
WO2025140265A1 (en) * 2023-12-26 2025-07-03 Wuxi Biologics (Shanghai) Co., Ltd. Combination of chimeric antigen receptor and dap10 in cell therapy
WO2026003135A1 (en) * 2024-06-27 2026-01-02 Genicity Limited Engineered lymphocytes expressing interleukin-15 and interleukin-21 and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
JPH0746994B2 (ja) 1984-10-04 1995-05-24 味の素株式会社 発酵法によるｌ−アミノ酸の製造法
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
CA2058820C (en) 1991-04-25 2003-07-15 Kotikanyad Sreekrishna Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells
JPH07501450A (ja) 1991-11-29 1995-02-16 モンサント　カンパニー 環状ジグアニレート代謝酵素
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
EP0672161B1 (en) 1992-11-05 1999-09-22 Xyrofin Oy Recombinant method and host for manufacture of xylitol
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
WO1996006926A1 (fr) 1994-08-30 1996-03-07 Ajinomoto Co., Inc. Procede pour produire de la l-valine et de la l-leucine
JP3966583B2 (ja) 1997-06-23 2007-08-29 協和醗酵工業株式会社 発酵法によるｌ−アミノ酸の製造法
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
ZA200503075B (en) 2002-11-07 2006-09-27 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
JP2013529627A (ja) 2010-06-24 2013-07-22 パンメド リミテッド ヒドロキシクロロキンまたはヒドロキシクロロキンおよび抗ウイルス剤の組合せを使用するｃ型肝炎ウイルス関連疾患の処置
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
NL2006359C2 (en) 2011-03-08 2012-04-24 Bird Engineering B V Genetically modified cell and process for use of said cell.
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
US9913627B2 (en) * 2013-01-29 2018-03-13 Becton, Dickinson And Company Specimen collection container having a fluid separation chamber
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
SG11201604784XA (en) 2013-12-13 2016-07-28 Genentech Inc Anti-cd33 antibodies and immunoconjugates
US20170335281A1 (en) 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
MX2017002205A (es) 2014-08-19 2017-08-21 Novartis Ag Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
RU2021118125A (ru) * 2014-12-29 2022-04-06 Новартис Аг Способы получения экспрессирующих химерный антигенный рецептор клеток
JP6849600B6 (ja) 2015-01-29 2021-06-30 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ キメラ抗原受容体、組成物及び方法
EP4286511A3 (en) 2015-06-12 2024-03-06 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
JP6821688B2 (ja) 2015-10-09 2021-01-27 ミルテニー・バイオテク・テクノロジー・インコーポレイテッドＭｉｌｔｅｎｙｉ Ｂｉｏｔｅｃ Ｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． キメラ抗原受容体および使用方法
CA3011538A1 (en) 2016-01-18 2017-07-27 Arisan Therapeutics Adamantane derivatives for the treatment of filovirus infection
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
CN117721084A (zh) * 2017-10-12 2024-03-19 美商生物细胞基因治疗有限公司 靶向多种抗原的复合嵌合抗原受体（cCAR）及其组成和使用方法
WO2019079339A1 (en) 2017-10-18 2019-04-25 Avalon Flaviviral Therapeutics (Hk) Limited COMPOSITIONS AND METHODS FOR BROAD SPECTRUM ANTIVIRAL THERAPY
IL321548A (en) * 2018-05-22 2025-08-01 Immunitybio Inc Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
WO2020055368A2 (en) 2018-09-12 2020-03-19 Istanbul Medipol Universitesi Usage of terpenic coumarin derived molecules in treating viral diseases
AU2019377461A1 (en) * 2018-11-06 2021-05-27 Washington University Chimeric antigen receptor memory-like (CARML) NK cells and methods of making and using same
EP3773918A4 (en) * 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
WO2020198128A1 (en) * 2019-03-22 2020-10-01 The Regents Of The University Of California Switchable chimeric antigen receptor-engineered human natural killer cells
US20200308248A1 (en) * 2019-03-26 2020-10-01 ST Phi Therapeutics Chimeric Natural Killer Cell Receptors and Method of Using Thereof

Similar Documents

Publication Publication Date Title
JP2024504728A5 (enExample)
JP2022109953A5 (enExample)
EP3472205B1 (en) Chimeric antigen receptor
US20250101080A1 (en) Chimeric antigen receptors and uses thereof
CN107406518B (zh) 嵌合抗原受体
CA2978381C (en) Chimeric antigen receptor (car) comprising a cd19-binding domain
US11692034B2 (en) CD47-CAR-T cells
JP2022523961A5 (enExample)
CN112074278B (zh) Bcma-car-t细胞
JP2024500847A5 (enExample)
US20200255494A1 (en) Cell
HRP20241535T1 (hr) Receptori koji pružaju ciljanu kostimulaciju za adoptivnu staničnu terapiju
EP3471770A1 (en) Tunable chimeric antigen receptors
JP2018523484A (ja) 細胞
JP2002521053A (ja) ヘテロミニ体
CN110114371A (zh) 嵌合抗原受体
EP3143040A1 (en) Glypican-3-specific t-cell receptors and their uses for immunotherapy of hepatocellular carcinoma
TW201841944A (zh) 4-1bbl變異體及包含其之融合蛋白
JP2024544559A5 (enExample)
CN112996819B (zh) 细胞分选系统及使用方法
TW202144396A (zh) 抑制性嵌合受體架構
JP2024504162A5 (enExample)
JP2022548112A5 (enExample)
JP2025515995A5 (enExample)
CN114286691B (zh) Cs1-抗体和抗cs1-car-t细胞